-
Mashup Score: 7It’s the Little Things: A Role for Bacteria in Cancer Treatment - 8 month(s) ago
Several recent studies suggest that the tiny organisms known as bacteria could be big allies in the war on cancer.
Source: www.aacr.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a breakthrough study, researchers presented encouraging progress in the treatment of #gliomas at #AACR2023. GD2-targeting CAR-T cells showed promising results, providing hope for potential transformative therapies: https://t.co/aCSe1xV3JL #breakthroughstudy https://t.co/aKFkJ4wbiC
-
-
Mashup Score: 1Novel Methylome Enrichment Platform Shows Promise Detecting Early-Stage and Low DNA-Shedding Solid Tumors - 10 month(s) ago
Michael Shusterman, MD, expands on the need for accurate early detection methods in solid tumors for which there aren’t proper surveillance tests, advantages of the unique methylation sequencing technique harnessed by this novel assay, and more.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Novel Methylome Enrichment Platform Shows Promise Detecting Early-Stage and Low DNA-Shedding Solid Tumors @nyulangone @AACR #AACR23 #AACR2023 https://t.co/CTRis2LJrS
-
-
Mashup Score: 0
Researchers are backing further investigation of 60 mg selinexor plus ruxolitinib based on positive phase 1/2 findings presented at the AACR Annual Meeting 2023.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Once-weekly #selinexor 60 mg + #ruxolitinib achieved rapid and deep spleen responses that were sustained and robust symptom improvements in patients with treatment-naïve #myelofibrosis. #AACR2023 #mpnsm | @cityofhope https://t.co/dF1zDtwcQ6
-
-
Mashup Score: 40N-of-1 Trials in Cancer Drug Development - 1 year(s) ago
Summary:. The current approaches for cancer drug development lag behind an accelerated need in the field for a fast and efficient method for evaluating drugs in the personalized medicine era. In that regard, N-of-1 studies emerge as a potential addition to the drug development arsenal, although there are several considerations before its broad application becomes feasible. In essence, N-of-1…
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @mgoudaMD: Thrilled to see our second manuscript during #AACR2023 now published in Cancer Discovery! @CD_AACR https://t.co/G5wkHb2m2g…
-
⭐️Huge congratulations to @mgoudaMD our amazing fellow @MDAndersonNews for the AACR 2023 Scholar-in-training award ! ⭐️Quadruple the happiness & excitement when your mentee wins an award @AACR #AACR23 @OncoAlert @Aiims1742 Read the paper https://t.co/3GzXgZHijL https://t.co/627DyPwxpF https://t.co/yK0wV8Knk5
-
N-of-1 Trials in Cancer Drug Development | Cancer Discovery | American Association for Cancer Research https://t.co/AG8gCOKZ6s
-
-
Mashup Score: 1AACR names president-elect for 2023-2024 - 1 year(s) ago
Patricia M. LoRusso, DO, PhD (hc), has been elected president-elect of American Association for Cancer Research for 2023-2024.LoRusso began her term on April 17.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CONGRATULATIONS: AACR names president-elect for 2023-2024. https://t.co/wEI1kN0Sp8 #AACR2023 #AACR23 @AACR #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0
Responses in 37% of patients previously treated with anti-PD-1/L1 agents, platinum chemotherapy
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
A preliminary clinical trial showed that more than a third of patients with previously treated head and neck #cancer responded to a novel bispecific #antibody. #AACR23 #AACR2023 @AACR https://t.co/KDb5qgGlMf
-
-
Mashup Score: 2
The addition of pembrolizumab to gemcitabine and cisplatin conferred a statistically significant and clinically meaningful survival benefit for patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 study. “We were encouraged to see the consistency of benefit across geographic regions, including non-Asian regions, and across PD-L1 expression
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pembrolizumab plus chemotherapy prolongs survival in advanced biliary tract cancer. https://t.co/n0vvFpvIgc #AACR2023 #AACR23 @AACR #HemOnc #OncAlert #MedEd #tractcancer
-
-
Mashup Score: 0OncLive - Clinical Oncology News, Cancer Expert Insights - 1 year(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@post_reddy, of @MoffittNews, discussed the environment of uveal melanoma that leads to metastasis growth on the liver. Check https://t.co/E5LOd0oiTe to hear more insights from @AACR #AACR2023 https://t.co/xHWbgmaSXP
-
-
Mashup Score: 2Perioperative durvalumab-based therapy reduces risk for adverse lung cancer outcomes - 1 year(s) ago
Patients with resectable non-small cell lung cancer who received perioperative durvalumab with neoadjuvant chemotherapy had significantly longer EFS and higher pathologic complete response rates than those who received chemotherapy alone.The combination also had a manageable safety profile consistent with previous studies, according to results of the randomized, double-blind phase 3 AEGEAN trial,
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Perioperative durvalumab-based therapy reduces risk for adverse lung cancer outcomes. https://t.co/RBCWFwBRmR #AACR2023 #AACR23 @AACR #HemOnc #OncAlert #MedEd
-
Emerging research suggests that bacteria could be modified to treat cancer. Learn about recent progress on this front on the #AACRBlog: https://t.co/YlfccD54Hd @UMNews #AACR2023 https://t.co/JUFwZdQoOt